Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 4/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | TSHR | P16473 | 3/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7034982 | 0.83 | KMT2A (0.47) | KMT2AMAPTMEN1CYP3A4CYP2C19 | |
| SCHEMBL10959895 | 0.83 | NPSR1 (0.50) | KMT2AMAPTMEN1CYP3A4CYP2C19 | |
| SCHEMBL10711856 | 0.82 | KMT2A (0.50) | KMT2AMAPTMEN1CYP3A4CYP2C19 | |
| SCHEMBL6626142 | 0.81 | KMT2A (0.46) | KMT2AMAPTMEN1CYP3A4CYP2C19 | |
| SCHEMBL11437979 | 0.79 | KMT2A (0.44) | KMT2AMAPTMEN1CYP3A4CYP2C19 | |
| SCHEMBL28966867 | 0.79 | ALDH1A1 (0.54) | KMT2AMAPTMEN1CYP3A4CYP2C19 | |
| SCHEMBL1067570 | 0.79 | NPSR1 (0.41) | KMT2AMAPTMEN1CYP3A4CYP2C19 | |
| SCHEMBL8599398 | 0.79 | KMT2A (0.41) | KMT2AMAPTMEN1CYP3A4CYP2C19 | |
| SCHEMBL6037525 | 0.78 | KMT2A (0.41) | KMT2AMAPTMEN1CYP3A4CYP2C19 | |
| SCHEMBL11676561 | 0.78 | NPSR1 (0.36) | KMT2AMAPTMEN1CYP3A4CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4704854-A2 | PRMT INHIBITOR COMPOUNDS AND THE USES THEREOF | Purdue Research Foundation (US) | 2026-03-11 | — | — | EP | disclosed |
| WO-2024229435-A2 | PRMT INHIBITOR COMPOUNDS AND THE USES THEREOF | PURDUE RESEARCH FOUNDATION (US) | 2024-11-07 | — | — | WO | disclosed |
| US-10265279-B2 | Combinations of LSD1 inhibitors for use in the treatment of solid tumors | ORYZON GENOMICS, S.A. (ES) | 2019-04-23 | — | — | US | disclosed |
| US-20190100552-A1 | INHIBITORS OF PROTEIN METHYLTRANSFERASE DOT1L AND METHODS OF USE THEREOF | Epizyme, Inc. | 2019-04-04 | — | — | US | disclosed |
| US-10112968-B2 | Inhibitors of protein methyltransferase DOT1L and methods of use thereof | Epizyme, Inc. (US) | 2018-10-30 | — | — | US | disclosed |
| US-20170281567-A1 | COMBINATIONS OF LSD1 INHIBITORS FOR USE IN THE TREATMENT OF SOLID TUMORS | HOFFMANN-LA ROCHE INC. (US) | 2017-10-05 | — | — | US | disclosed |
| US-20170137455-A1 | INHIBITORS OF PROTEIN METHYLTRANSFERASE DOT1L AND METHODS OF USE THEREOF | Epizyme, Inc. | 2017-05-18 | — | — | US | disclosed |
| US-20160168185-A1 | NON-RIBOSE CONTAINING INHIBITORS OF HISTONE METHYLTRANSFERASE DOT1L FOR CANCER TREATMENT | BAYLOR COLLEGE OF MEDICINE (US) | 2016-06-16 | — | — | US | disclosed |
| US-20150284422-A1 | INHIBITORS OF PROTEIN METHYLTRANSFERASE DOT1L AND METHODS OF USE THEREOF | Epizyme, Inc. | 2015-10-08 | — | — | US | disclosed |
| US-5283362-A | Reacting with an amine, terminating the reaction before the formation of by-product | CHEMIE LINZ GESELLSCHAFT M.B.H. (AT) | 1994-02-01 | — | — | US | disclosed |
| US-4666529-A | Method for reducing combustion chamber deposits from an internal combustion engine | SHELL OIL COMPANY (US) | 1987-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150284422-A1 | INHIBITORS OF PROTEIN METHYLTRANSFERASE DOT1L AND METHODS OF USE THEREOF | DOT1L, PRMT1, CARM1 | KMT2A 28/4885MAPT 130/4885MEN1 2681/4885 |
| US-10265279-B2 | Combinations of LSD1 inhibitors for use in the treatment of solid tumors | KDM1B, DOT1L, KDM1A | KMT2A 14/4885MAPT 3454/4885MEN1 1891/4885 |
| US-10112968-B2 | Inhibitors of protein methyltransferase DOT1L and methods of use thereof | DOT1L, PRMT1, CARM1 | KMT2A 28/4885MAPT 130/4885MEN1 2681/4885 |
| US-20190100552-A1 | INHIBITORS OF PROTEIN METHYLTRANSFERASE DOT1L AND METHODS OF USE THEREOF | DOT1L, PRMT1, CARM1 | KMT2A 28/4885MAPT 130/4885MEN1 2681/4885 |
| US-20170137455-A1 | INHIBITORS OF PROTEIN METHYLTRANSFERASE DOT1L AND METHODS OF USE THEREOF | DOT1L, PRMT1, CARM1 | KMT2A 28/4885MAPT 130/4885MEN1 2681/4885 |
| US-20170281567-A1 | COMBINATIONS OF LSD1 INHIBITORS FOR USE IN THE TREATMENT OF SOLID TUMORS | KDM1B, DOT1L, KDM1A | KMT2A 14/4885MAPT 3454/4885MEN1 1891/4885 |
| US-20160168185-A1 | NON-RIBOSE CONTAINING INHIBITORS OF HISTONE METHYLTRANSFERASE DOT1L FOR CANCER TREATMENT | DOT1L, CARM1, NSD1 | KMT2A 16/4885MAPT 3299/4885MEN1 2460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.